Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") announces the relevant matters as follows: its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has recently obtained the Approval Notice for the Marketing Application of Chemical Active Pharmaceutical Ingredient for Nicorandil, which was officially issued and approved by the National Medical Products Administration (NMPA).
I. Basic Information of the Active Pharmaceutical Ingredient (API)
Name of the chemical API: Nicorandil
Notice No.: 2024YS01274
Registration No.: Y20230000829
Acceptance No.: CYHS2360684
Registration Standard No. of the chemical API: YBY75392024
Validity Period: 18 months
Packaging Specification: 2kg/bag
Application Item: Marketing application for domestically produced chemical API
Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, this product meets the relevant requirements for drug registration and is approved for registration. The quality standard, label and production process shall be implemented in accordance with the attached documents.
Validity Period of the Notice: Until December 10, 2029
II. Other Relevant Information
Preparations containing Nicorandil are mainly indicated for the treatment of angina pectoris.












